Insider · CIK 0001579310
Keith T. Flaherty
Files at KNTE (Kinnate Biopharma Inc.). First filing -, latest -.
In brief
Keith T. Flaherty files SEC Form 4 as director at KNTE (Kinnate Biopharma Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Keith T. Flaherty has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 3, 2024 | KNTE Kinnate Biopharma Inc. | DDisposition to issuer Common Stock | -66,377 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | KNTE Kinnate Biopharma Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -32,064 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | KNTE Kinnate Biopharma Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -56,112 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | KNTE Kinnate Biopharma Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -11,391 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | KNTE Kinnate Biopharma Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -20,250 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | KNTE Kinnate Biopharma Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -20,250 | - | - | 0 | Apr 5, 2024 |
| Apr 3, 2024 | KNTE Kinnate Biopharma Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -25,000 | - | - | 0 | Apr 5, 2024 |
| Jun 12, 2023 | KNTE Kinnate Biopharma Inc. | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jun 13, 2023 |
Questions about Keith T. Flaherty
Answered from the filings on this page, as of the latest one.
Is Keith T. Flaherty buying or selling?
Keith T. Flaherty has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Keith T. Flaherty's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Keith T. Flaherty has 0.
Where does Keith T. Flaherty file Form 4?
Keith T. Flaherty has filed Form 4 at KNTE (Kinnate Biopharma Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.